RxDoctor Payments Data

Luis Concepcion, MD

Hematology & Oncology · Paducah, KYNPI 1194778449

Payments from drug & device makers

$3,500in general payments, 2019–2025

Across 199 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$350
  • Novartis$350
  • Astellas Pharma US Inc$250
  • AstraZeneca$206
  • Johnson & Johnson$175
  • Daiichi Sankyo Inc.$147
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,23092%
  • Education$2718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,500 in reported general payments places this provider in the 30th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$165,633
Medicare patients
417
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib40$649,848
XtandiEnzalutamide52$635,550
CabometyxCabozantinib S-Malate18$436,866
IbrancePalbociclib23$373,602
Abiraterone Acetate115$343,544
ErleadaApalutamide20$283,776
Lenalidomide15$205,752
VenclextaVenetoclax12$42,416
XareltoRivaroxaban42$31,829
Ondansetron Hcl159$9,748
EliquisApixaban13$7,844
Anastrozole301$3,829
Exemestane26$3,453
Letrozole180$3,160
Dronabinol15$2,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$84$649,84840 claims
Astellas Pharma US IncXtandi$250$635,55052 claims
Exelixis Inc.Cabometyx$73$436,86618 claims
PfizerIbrance, Eliquis$350$381,44636 claims
Johnson & JohnsonErleada, Xarelto$175$315,60562 claims
AbbVieVenclexta$71$42,41612 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$15$53637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →